Lexaria Bioscience (LEXX) Expected to Announce Earnings on Tuesday

Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) is anticipated to release its Q4 2026 results on Tuesday, November 24th. Analysts expect the company to post earnings of ($0.90) per share and revenue of $0.05 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Tuesday, November 24, 2026 at 12:00 AM ET.

Lexaria Bioscience Stock Down 10.2%

NASDAQ LEXX opened at $4.03 on Friday. The firm has a market cap of $8.50 million, a price-to-earnings ratio of -0.79 and a beta of 0.60. The business has a 50-day moving average price of $3.48 and a 200-day moving average price of $8.41. Lexaria Bioscience has a twelve month low of $2.43 and a twelve month high of $21.60.

Analyst Ratings Changes

LEXX has been the topic of several recent analyst reports. Weiss Ratings downgraded Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Wall Street Zen upgraded Lexaria Bioscience to a “sell” rating in a research note on Saturday, October 10th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.50.

Read Our Latest Stock Analysis on LEXX

About Lexaria Bioscience

(Get Free Report)

Lexaria Bioscience is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics. The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments.

Featured Stories

Earnings History for Lexaria Bioscience (NASDAQ:LEXX)

Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.